Schipper J P
Ziekenhuis Bethesda, afd. Neurologie, Dr.G.H.Amshoffweg i, 7909 AA Hoogeveen.
Ned Tijdschr Geneeskd. 2007 Apr 14;151(15):852-5.
Two large randomised clinical trials were published in March 2006 that evaluated the effect of natalizumab on the incidence of disease exacerbation in patients with multiple sclerosis (MS). Both trials showed that natalizumab reduces the incidence of MS exacerbations, but it is unclear whether patients ultimately benefited from treatment. It is clear that natalizumab is associated with serious adverse events, such as progressive multifocal leukoencephalopathy. Therefore, the use of natalizumab in patients with MS cannot be considered advisable at this time.
2006年3月发表了两项大型随机临床试验，评估那他珠单抗对多发性硬化症（MS）患者疾病加重发生率的影响。两项试验均表明那他珠单抗可降低MS加重的发生率，但尚不清楚患者最终是否从治疗中获益。很明显，那他珠单抗与严重不良事件相关，如进行性多灶性白质脑病。因此，目前不能认为在MS患者中使用那他珠单抗是可取的。
